PCSK9 inhibitors: Specific studies are mandatory to prove efficacy and safety in CKD
Chronic kidney disease (CKD) is associated with a substantially increased risk for the development of atherosclerotic cardiovascular disease (CVD). Accordingly, cardiovascular mortality is increased even in the earliest stages of CKD. In the general population and in CKD patients, high plasma levels of low-density lipoprotein cholesterol (LDL-C) are crucially involved in the initiation and progression of atherosclerotic vascular lesions. In addition, it has been documented that LDL accumulating in the vascular wall is prone to be post-translationally modified; e.g. by oxidation or carbamylation, which is particularly relevant to patients with CKD.
Lowering LDL-C by use of statins and/or ezetimibe represents the gold standard of lipid-lowering therapy with a great body of evidence from several large clinical trials. Statin therapy reduces cardiovascular events in patients with normal and impaired kidney function alike, while the evidence for patients on maintenance haemodialysis is rather weak. Moreover, reduced kidney function may represent a risk factor for statin-related adverse outcomes such as myopathy.
The inhibition of proprotein convertase subtilisin/kexin type 9 serine protease (PCSK9) represents a novel lipid-lowering tool directly modulating hepatic LDL metabolism. PCSK9 protein reduces the expression of LDL-receptor (LDLR) on the surface of liver cells and, thereby, decreases cellular uptake of LDL and thus its clearance from the circulation. Currently, the monoclonal antibodies evolocumab and alirocumab are approved PCSK9 inhibitors. Despite maximum-tolerated statin therapy, they efficiently further reduce LDL-C plasma levels without any major adverse effects.
Moreover, in large clinical outcome trials, both antibodies have been proven to lower cardiovascular events. Notably, the LDL-lowering capacity was independent of baseline kidney function and also efficient in patients with moderate CKD. However, patients with severely impaired kidney function–i.e. the population at the highest cardiovascular risk–have been excluded from those trials. The relevance of the LDL-independent effects of PCSK9 inhibitors such as lowering lipoprotein(a) or ameliorating dyslipidaemia in patients with nephrotic syndrome has to be determined.
“In particular, in patients with advanced CKD, the high annual costs of therapy with PCSK9 inhibitors have to be balanced against weak evidence for a benefit”, explains Thimoteus Speer, corresponding author of the review PCSK9 in kidney disease . “Specific studies in CKD patients are mandatory to prove the efficacy and safety of PCSK9 inhibitors and to determine their ability to improve outcomes in these patients.”
 Schmit D, Fliser D, Speer R et al. PCSK9 in kidney disease. NDT 2019. June 13 [epub]
With more than 7,000 active members, the ERA-EDTA is one of the biggest nephrology associations worldwide leading European nephrology and one of the most important European Medical Associations. It organises annual congresses and a Scientific Education Interactive Day (SEID), it produces guidelines, it collects data and performs epidemiological studies through its Registry. It supports fellowships and research projects. Its publications are NDT and CKJ (this last journal is Open Access). The ERA-EDTA also has an online Educational platform: the European Nephrology Portal (ENP) which includes [email protected] The 2020 Congress will be held June 6-9 in Milan (Italy). Visit the booth to receive more information!
Web site: http://www.